CADE proposes remedy for GSK/Pfizer
The investigative arm of Brazil’s competition authority has raised concerns that GlaxoSmithKline’s pending acquisition of Pfizer’s consumer healthcare division could lead to higher prices for simple antacids.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.